{'fraction_non_alphanumeric': 0.05568233683249658, 'fraction_numerical': 0.051574623459607484, 'mean_word_length': 5.05524861878453, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Risk of osteoporosis/osteopenia events in patients newly diagnosed with neuroendocrine tumors.

e16602 Background: Neuroendocrine tumors (NET) derive from peptides- and hormones-producing cells scattered throughout the body. In excess, these can lead to many clinical manifestations. This study evaluated patient's risk of experiencing osteoporosis/osteopenia in the first three years post diagnosis, comparing NET to general non-cancer patients.


METHODS
This is a retrospective matched-control cohort study utilizing SDI's claims databases. NET patients consisted of adults newly diagnosed with one of the following specific NET ICD9-CM codes: 157.4, 209.xx, 258.01, 259.2 from 2001 to 2007. Non-cancer controls were matched 2 to 1 with NET patients on age, gender, region, and hospital data availability. Risk of osteoporosis/osteopenia related diagnosis or procedures were captured during the 3-year post index period, and were analyzed using Cox proportional hazards and logistic regressions adjusting for baseline comorbidity index, age, gender, region, payer, and physician specialty/academic affiliation.


RESULTS
The study sample consisted of 1,762 newly diagnosed NET (median age=61 years, 59.3% female, 70.4% commercially insured and 28.8% Medicare patients) and 3,524 matched control patients. During the 3-year follow-up, 9.1% of NET and 8.9% of control patients experienced osteoporosis/osteopenia events (p=0.838). Osteoporosis/osteopenia event rates were markedly higher in NET patients (5.0%) than controls (1.7%, p=0.002) in the patients aged less than 50 years (n=1,077, 359 NET and 718 control patients). In this younger patient group, NET patients were more than three times likely to have osteoporosis/osteopenia events than controls (hazard ratio=3.38, 95% CI: 1.44-7.91, p=0.005; odds ratio=3.24, 95% CI: 1.36-7.73, p=0.008).


CONCLUSIONS
Osteoporosis/osteopenia events were much more prevalent in NET patients post diagnosis than in non-cancer controls aged 50 years or less. The results of this study suggest a higher incremental risk of osteoporosis in NET patients, and warrant additional investigation in future studies, as well as greater clinical awareness.